Welcome to our dedicated page for Grifois, S.A. news (Ticker: GRFS), a resource for investors and traders seeking the latest updates and insights on Grifois, S.A. stock.
Grifols, S.A. (NASDAQ: GRFS) is a leading global healthcare company headquartered in Barcelona, Spain, with a legacy of over 75 years dedicated to improving the health and well-being of people around the world. As a vertically integrated plasma derivative producer, Grifols collects plasma and manufactures life-saving plasma-derived therapies. The company’s commitment to innovation and patient care has established it as a benchmark in the plasma collection market and transfusion medicine.
Grifols operates through three main business divisions:
- Bioscience: This division encompasses all plasma-related activities including research, development, collection, production, and sales of plasma-derived therapies. The acquisition of Talecris in 2011 and Biotest in 2022 significantly expanded the product portfolio, with the biopharma business contributing 84% of sales in 2023.
- Diagnostic: Providing innovative solutions for safe transfusions, therapy monitoring, and the detection of infectious and autoimmune diseases, this division focuses on research and novel technologies to enhance treatment outcomes and laboratory efficiency.
- Hospital: Specializing in non-biological pharmaceutical products, the Hospital division meets the diverse needs of healthcare facilities worldwide.
Grifols' latest advancements include the successful phase 4 trial of XEMBIFY® for primary immunodeficiencies, showing non-inferiority in Ig levels with biweekly dosing compared to weekly dosing. Additionally, the phase 2 trial of ABvac40, a potential Alzheimer’s vaccine, demonstrated a robust immune response and some cognitive benefits in patients with early-stage Alzheimer’s disease.
With a global presence in more than 100 countries, Grifols continues to grow its network of plasma donation centers, boasting over 390 locations across North America, Europe, Africa, the Middle East, and China. The company's economic impact in its core countries of operation was EUR 9.6 billion in 2022, generating 193,000 jobs including indirect and induced employment.
Grifols' class A shares are listed on the Spanish Stock Exchange as part of the Ibex-35 (MCE:GRF), while non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and the U.S. NASDAQ through ADRs (NASDAQ:GRFS).
Grifols has finalized its agreement to acquire the remaining 56% of GigaGen for USD 80 million, strengthening its innovation strategy in biotherapeutics. GigaGen specializes in recombinant biotherapeutic medicines and has a promising pipeline, including GIGA-2050, an immunoglobulin for COVID-19, now entering Phase 1 trials in the U.S. The acquisition aligns with Grifols’ commitment to sustainable growth and expands its portfolio of advanced therapies, supporting patient health globally.
Grifols has finalized its acquisition of GigaGen for USD 80 million, securing 100% ownership. This move strengthens Grifols' innovation strategy, focusing on novel therapies derived from antibodies. GigaGen is recognized for its groundbreaking recombinant biotherapeutic medicines, including GIGA-2050, aimed at treating COVID-19, which is set for a Phase 1 trial. The acquisition aligns with Grifols' long-term growth plan and its commitment to integrating promising R&D projects.
Grifols, a leader in plasma-derived therapies, announced the launch of Plasmatology, the first scientific journal dedicated to plasma science, coinciding with the 70th anniversary of plasmapheresis. The journal, starting March 9, aims to become a key reference for plasma research and will publish peer-reviewed articles. Grifols will support the journal with an educational grant over two years. This initiative reflects the company's commitment to advancing plasma science and honors its founder's legacy in the field.
Grifols announced the launch of the world's first scientific journal dedicated to plasma science, coinciding with the 70th anniversary of the plasmapheresis technique. Titled Plasmatology, the journal aims to be the leading reference in plasma research, publishing peer-reviewed articles covering various topics in plasma science. Grifols will provide an educational grant over the next two years to support the journal's establishment. This initiative reinforces Grifols' commitment to research and scientific advancement in plasma-derived therapies, enhancing its leadership position in the industry.
Grifols (NASDAQ: GRFS) has been recognized as the top vendor in IV Workflow Management for its PharmacyKeeper Verification software in the 2021 Best in KLAS report, marking its fifth consecutive year of receiving this accolade. This ranking reflects exceptional scores in quality, value, and user ease among a range of hospitals and systems. The company emphasizes its commitment to enhancing pharmacy operations, including a recent initiative to support COVID-19 vaccine preparation. Grifols is dedicated to safety and efficiency in healthcare settings through innovative solutions.
Grifols, a global leader in plasma-derived medicines, announced its PharmacyKeeper Verification software ranked No. 1 in IV Workflow Management in the 2021 Best in KLAS report, marking its fifth consecutive year at the top. This accolade reflects exceptional scores in quality, value, and ease of use across various healthcare facilities. Grifols has committed to supporting clients with COVID-19 vaccine workflows, showcasing its dedication to industry needs. The Best in KLAS rating, based on provider feedback, signifies Grifols' excellence in healthcare technology and services.
Grifols has announced a clinical trial set to commence in February 2021 in Spain to evaluate the safety and efficacy of a new COVID-19 treatment utilizing Gamunex®-C, which contains anti-SARS-CoV-2 polyclonal antibodies from recovered plasma donors. The trial will involve approximately 800 asymptomatic patients testing positive for the virus. This treatment is designed to offer immediate post-exposure protection, particularly for vulnerable populations. Results are anticipated in Spring 2021, with the potential to enhance existing vaccination efforts.
Grifols (NASDAQ: GRFS) announced a partnership with TRC Healthcare on November 12, 2020, to enhance pharmacy education. This collaboration integrates Grifols' PharmacyKeeper, a leading IV Workflow Management system, with TRC's educational resources. The aim is to improve patient safety and care by providing pharmacists with up-to-date drug information and training. The partnership underscores Grifols' commitment to advancing IV room operations and reinforces its leadership position in the pharmacy technology market.
Grifols has commenced a randomized controlled clinical trial for its anti-SARS-CoV-2 hyperimmune globulin aimed at treating COVID-19. Funded by NIAID, this Phase 3 trial will assess safety, efficacy, and tolerability in 500 hospitalized adults across 58 hospitals in 18 countries. This treatment leverages convalescent plasma from recovered COVID-19 patients, potentially enhancing immune response to reduce severe illness risk. Grifols has quickly established a convalescent plasma collection program and is actively participating in over 25 COVID-19 initiatives.
FAQ
What is the current stock price of Grifois, S.A. (GRFS)?
What is the market cap of Grifois, S.A. (GRFS)?
What does Grifols, S.A. specialize in?
Where is Grifols headquartered?
What are the main business divisions of Grifols?
What recent advancements has Grifols made?
What is Grifols' market presence?
How has Grifols impacted the economy?
Where are Grifols' shares listed?
What are the core areas of treatment Grifols focuses on?
What is XEMBIFY®?
What is the significance of the ABvac40 trial?
